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BACKGROUND: The proinflammatory chemokine
CXCL10, in addition to its chemotactic properties, is
also involved in the stimulation of natural killer and
T-cell migration in Mycobacterium tuberculosis in-
fection. In this study, our experiments were designed
to determine the role of interferon (IFN)-ab in the
production of CXCL10 by human monocytes infected
with Mycobacterium bovis bacillus Calmette
/Gue ´rin
(BCG).
Methods: The concentrations of CXCL10 in culture
supernatants of monocytes infected with M. bovis
BCG were determined by enzyme-linked immunosor-
bent assay. CXCL10 mRNA levels were determined by
the reverse transcription-polymerase chain reaction
method.
Results: We have shown the induction of CXCL10
following infection with M. bovis BCG in a dose-
dependent and time-dependent manner. Importantly,
the secretion of CXCL10 in response to M. bovis was
increased by IFN-a. These results were further con-
firmed by the fact that the addition of an anti-IFN-ab
neutralizing antibody completely reversed the stimu-
latory effect, whereas an isotype-matched control
antibody had no significant effect on CXCL10 secre-
tion. It is important to note that no significant effect
of type I IFN on CXCL8 production in M. bovis-
infected monocytes was observed. This was consis-
tent with the finding by the reverse transcription-
polymerase chain reaction method that treatment
with anti-IFN-a/b antibodies potentially inhibited
CXCL10 mRNA levels, whereas no significant effect
was observed on CXCL8 mRNA. Moreover, in THP-1
monocytes and THP-1 macrophages, the addition of
exogenous IFN-a stimulated CXCL10 secretion.
Conclusions: Collectively, these results indicate that
the type I IFN may play an important role to modulate
the expression of CXCL10 in M. bovis BCG infection.
Studies on M. bovis-induced chemokine secretion
could provide important insight into the regulation
of the immune response against tuberculosis.
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Introduction
The proinflammatory response of infected human
monocytes is an important early host defense me-
chanism against mycobacterial infection. Recently, it
has been estimated that one-third of the world’s
population is infected with Mycobacterium tubercu-
losis.
1 Mycobacterium bovis bacillus Calmette/
Gue ´rin (BCG) is currently administered as the only
available vaccine for the prevention of tuberculosis in
humans.
2 Protective immunity against tuberculosis
requires productive infection of the host by M. bovis
BCG. Infection of human cells with M. bovis induces
release of various chemoattractants. Chemokines are
recently identified chemotactic cytokines and can be
divided into four subfamilies according to the N-
terminal cysteine positioning in their amino acid
sequence: CXC, CC, CX3C, and C.
3 Chemokines
induce changes in target cell membrane protein
composition, thus enhancing chemotaxis of leuko-
cytes through the vascular endothelium into the
inflamed tissues. It has been reported that CCL3,
CCL4, CCL5, and CXCL8 are released by human
alveolar macrophages upon infection with M. tuber-
culosis.
4 We recently reported that human monocytes
infected with M. bovis stimulate the secretion of
CXCL8.
5,6 Increased chemokine secretion has been
observed in monocytes and polymorphonuclear
granulocytes after infection with M. tuberculosis.
79
Moreover, it has been shown that M. tuberculosis-
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343induced chemokine production from macrophages is
regulated by different factors, such as host cell
surface molecules,
10 and mycobacterial cell wall
components.
11
It has also been demonstrated that interferon (IFN)
may induce the expression of certain chemokines
genes, such as those of CXCL9, CXCL10, and
CXCL11.
12,13 IFN have been divided into two classes
(type I and type II) on the basis of their structure,
function, and cellular origin. Both types are involve
in different mechanisms of innate and adaptive
immunity.
1416 The IFN-a/b system helps host de-
fense against M. tuberculosis in mice.
17 Recent
studies have highlighted the production of type I
IFN following M. tuberculosis infection.
18,19 How-
ever, it is not known whether the expression of
chemokines during infection of human monocytes
with M. bovis is dependent on type I IFN. In this
study, we have investigated the secretion of CXCL10
during infection of human monocytes with M. bovis.
Furthermore, we evaluated the effect of IFN-a/b on
the production of chemokines from M. bovis-infected
human monocytes.
Materials and methods
Reagents
Recombinant IFN-a and control antibody isotype
were purchased from Sigma-Aldrich (St Louis, MO,
USA). Rabbit polyclonal antiserum raised against IFN-
a and IFN-b were obtained from PBL Biomedical
Laboratories (New Brunswick, NJ, USA). Live M.
bovis BCG, Danish Strain 1331 was kindly supplied
by Dr J. Ruiz-Puente (Birmex, Me ´xico). BCG was
grown at 378C in Sauton medium using stationary
tissue culture flasks. Mycobacterial viability, as as-
sessed by the number of colony-forming units, was
60/70%.
Cell culture
Peripheral blood mononuclear cells were isolated
from healthy donors by density centrifugation over
Ficoll-Hypaque gradient (Histopaque; Sigma) (d /
1.007). Human monocytes were purified by positive
selection with magnetic microbead-coated antibody
(Miltenyi Biotec, Gladbach, Germany). Cells were
incubated with beads conjugated to monoclonal
mouse anti-human CD14 antibody (Leu-3a). The
recovered primary cells were  /96% CD14
 cells as
determined by flow cytometry with anti-CD14 anti-
body. Viability, as determined by trypan blue exclu-
sion test, was  /97%. THP-1 cells were obtained from
the American Type Culture Collection. Cells were
then cultured in fresh RPMI 1640 medium supple-
mented with 2 mM l-glutamine, 100 U/ml of peni-
cillin, 100 mg/ml of streptomycin, and 10% fetal calf
serum in a 5% CO2 incubator at 378C. THP-1 cells
were maintained in logarithmic growth (between 2 /
10
5 cells/ml and 10
6 cells/ml) by passage every 3/4
days. Infection of cells with M. bovis was performed
at a multiplicity of infection (MOI) of 5, unless
otherwise stated.
Uninfected cells were cultured and harvested in
parallel, and used as controls. In certain experiments,
cultured cells were incubated with M. bovis alone or
in the presence of increasing concentrations of
exogenous IFN-a. Neutralizing antibody IFN-a/b
was added at different concentrations to some
cultures.
Chemokine detection
The culture supernatants from control and M. bovis-
infected cell cultures were harvested at different
times after infection, centrifuged to remove any
debris, were filtered (0.2-mm filters), and were stored
at  /208C until use. Levels of CXCL8, and CXCL10 in
each of the supernatants were determined using the
kit human CXCL8 or CXCL10 enzyme-linked immu-
nosorbent assay (ELISA) system (R&D System, Min-
neapolis, MN, USA). The ELISA assays were carried
out according to the manufacturer’s instructions.
Optical density readings were obtained with a
microplate reader (model Labsystems Multiskan MS,
Finland).
Reverse transcription-polymerase chain reaction
mRNA expression of CXCL10 and CXCL8 in M. bovis-
infected monocytes was analyzed by the reverse
transcription (RT)-polymerase chain reaction (PCR)
method. Cells were treated with anti-IFN-ab (10 mg/
ml), and were then infected with M. bovis at MOI /5.
Total RNA from cells was isolated by the method of
Chomczynski and Sacchi.
20 Briefly, total RNA was
extracted with TRIzol (Life Technologies, Rockville,
MD) for 5 min at room temperature, transferred to a
microcentrifuge tube, and then 200 ml of cloroform
was added, vortex mixed, and incubated for 10 min.
After centrifugation for 5 min, the aqueous layer was
transferred to a fresh tube, and RNA was precipitated
by adding an equal volume of isopropanol. After
centrifugation, the RNA pellet was dried and dis-
solved in 50 ml of sterile water. The RNA concentra-
tion was determined by optical density
measurements. One microgram of RNA was reversi-
bly transcribed using random hexamer primers
(GIBCO BRL, Rockville, MD) and Superscript II
reverse transcriptase (GIBCO BRL). The resulting
cDNA was subjected to PCR, for a total of 20 cycles
in the standard reaction mixture using Taq DNA
polymerase and the appropriate CCXL8 or CXCL10
primers (Clontech Laboratories, Palo Alto, CA, USA).
P. M. Samperio et al.
344 Mediators of Inflammation Vol 13  2004An aliquot of the amplified product was run on a 2%
agarose gel in TBE. After electrophoresis, the gel was
stained for 5 min in ethidium bromide (1%) and
photographed. PCR primers for GAPDH were used as
an internal control.
Statistical method
Data are expressed as the mean9 /standard error of
the mean of at least three independent experiments
using cells from different individuals. Comparisons
between groups were made by analysis of variance.
Comparisons between two groups were performed
using Student’s t test. pB /0.01 was considered
statistically significant.
Results
Production of CXCL10 by human monocytes
infected with M. bovis BCG
In the first set of experiments, we examined the
CXCL10 secretion of human monocytes following
stimulation with M. bovis at MOI /5, MOI /3,
MOI /1, or MOI /0.1. As indicated in Fig. 1A,
CXCL10 production was clearly detected in a dose-
dependent manner after infection with M. bovis and a
maximal secretion was reached with MOI /5o f
M. bovis. No CXCL10 secretion was observed in
the absence of stimulation. There was no further
significant increase of CXCL10 secretion at higher
doses of M. bovis (data not shown). Next, we
analyzed the kinetic of CXCL10 secretion in human
monocytes during M. bovis infection. Human mono-
cytes were infected with M. bovis at MOI /5 and
cell culture supernatants were collected at different
time points after infection to determine the concen-
tration of CXCL10 by ELISA. As shown in Fig. 1B,
human monocytes infected with M. bovis showed
that CXCL10 production was in a time-dependent
manner.
Effect of type I IFN on CXCL10 production in M.
bovis-infected human monocytes
Because IFN-ab has been shown to be able to induce
the expression of certain chemokine genes,
12,13 we
next sought to determine whether exogenous IFN-a
regulates the CXCL10 secretion in M. bovis-infected
human monocytes. Human monocytes were infected
with M. bovis at MOI /5 and treated with increasing
concentrations of IFN-a. As shown in Fig. 2A, the
production of CXCL10 in response to M. bovis
was increased by IFN-a. This amount was significant
(pB /0.01). To further evaluate the specificity of the
effect of IFN-a on M. bovis-induced CXCL10 produc-
tion, a neutralizing antibody to IFN-ab (10 mg/ml)
or an isotype-matched control antibody (10 mg/ml)
was added to M. bovis-infected monocytes and
treated with IFN-a (1000 U/ml) for 24 h at 378C. As
indicated in Fig. 2B, stimulation of M. bovis-mediated
CXCL10 secretion by IFN-a (67% increment) was
completely neutralized with 10 mg of anti-IFN-
ab antibody/ml. In contrast, an isotype-matched
control immunoglobulin G1 antibody was without
effect (Fig. 2B).
In order to determine whether the effect of type I
IFN would also be observed on other chemokines
secreted in M. bovis-infected human monocytes,
we analyzed the production of CXCL8 in the super-
natants of M. bovis-infected human monocytes in the
presence or absence of increasing concentrations of
FIG. 1. (A) Dose-dependent and (B) time-dependent expres-
sion of CXCL10 by human monocytes infected with M. bovis.
The dose-dependent effect was studied using human mono-
cytes (10
6/well) cultured in medium alone or infected with
M. bovis at MOI /5, MOI /3, MOI /1, or MOI /0.1. CXCL10
secretion was measured by ELISA 24 h after infection.
*pB /0.01 compared with the value obtained with medium
alone. The time-dependent effect was evaluated using hu-
man monocytes infected with M. bovis at MOI /5 and cell
culture supernatants were collected at different time points
after infection and analyzed for CXCL10 secretion by ELISA.
The results are means9 /standard errors of the means for four
independent experiments.
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effect was detected in this other chemokine.
We next sought to analyze the effect of IFN-ab
system on monocytes and macrophages, since both
cell types are exposed to infection by mycobacteria
in vivo. We analyzed the effect of IFN-a on M. bovis-
induced secretion of CXCL10 using the THP-1 cell
line, which has long been used to study phorbol
ester-induced monocyte-to-macrophage differentia-
tion.
21 THP-1 macrophages (phorbol ester-treated)
and THP-1 monocytes (untreated) were infected with
M. bovis at MOI /5 in the presence or absence of
IFN-a. In accordance with primary cell experiments,
the addition of 1000 U/ml of IFN-a to THP-1
macrophages and THP-1 monocytes increased
CXCL10 secretion in M. bovis-infected cells (Fig. 4).
It is important to note that the effect of IFN-a was
more significant in THP-1 macrophages.
IFN-ab effect on CXCL10 mRNA expression
To further study the effect of type I IFN in CXCL10
gene expression, total cellular RNA was isolated from
M. bovis-infected human monocytes and treated with
10 mg/ml of a neutralizing anti-IFN-ab antibody. The
FIG. 2. Effects of exogenous type I IFN on CXCL10 production
in M. bovis-infected human monocytes. (A) Human mono-
cytes (10
6/well) were cultured in medium alone or infected
with M. bovis at MOI /5, and were treated with increasing
concentrations of exogenous IFN-a for 24 h at 378C. Cell
culture supernatants were harvested and CXCL10 protein
was measured by ELISA. *pB /0.01 compared with the value
obtained with medium alone. (B) Human monocytes were
treated with exogenous IFN-a (1000 U/ml) in the presence or
absence of a neutralizing antibody to IFN-ab or an isotype-
matched control antibody. Cell culture supernatants were
collected 24 h after M. bovis infection and analyzed with
CXCL10-speciﬁc ELISAs. The results represent the means9 /
standard errors of the means of ﬁve separate experiments.
The number in parentheses indicates the percentage of
increment by IFN-a with respect to M. bovis cultures.
 /, present; /, absent.
FIG. 3. Effect of recombinant IFN-a on M. bovis-mediated
CXCL8 secretion. Human monocytes were cultured in med-
ium alone or infected with M. bovis at MOI /5, and treated
with increasing concentrations of exogenous IFN-a. Cell
culture supernatants were harvested after 24 h and CXCL8
protein was measured by ELISA. Results of ELISAs are
expressed as pg/10
5 cells, and are means9 /standard errors
of the means for six independent experiments.
FIG. 4. Effect of the IFN-ab system on M. bovis-induced
secretion of CXCL10 using the THP-1 cell line. THP-1 macro-
phages and THP-1 monocytes were infected with M. bovis at
MOI /5 in the presence or absence of 1000 U/ml of
exogenous IFN-a. Cell culture supernatants were harvested
and CXCL10 protein was measured by ELISA. The results are
means9 /standard errors of the means for six independent
experiments. *pB /0.01 compared with the value obtained
with M. bovis alone.  /, present;  /, absent.
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measured by the RT-PCR method. Controls were
treated either with medium or with M. bovis alone. As
shown in Fig. 5A,B, control cells treated with medium
expressed undetectable constitutive levels of CXCL10
or CXCL8 mRNA, whereas M. bovis induced signifi-
cant CXCL10 or CXCL8 mRNA expression in human
monocytes. It is important to note that neutralization
of type I IFN reduced CXCL10 mRNA expression at 24
h after M. bovis infection (Fig. 5A). In contrast, no a
major change in the mRNA levels in M. bovis-induced
CXCL8 was detected (Fig. 5B). These results are
compatible with the aforementioned results obtained
by ELISA.
Discussion
There is growing evidence that chemokines play an
important role in the organization of the immune
system.
22,23 CXCL10 is a recently identified chemo-
kine that attracts Th1-activated and Tc-activated
lymphocytes and natural killer cells in M. tuberculosis
infection.
24 We have demonstrated here for the first
time that, following interaction with M. bovis, the
human monocytes produced significant amounts of
CXCL10. Importantly, we demonstrated that M. bovis-
induced CXCL10 secretion is upregulated by the
addition of exogenous type I IFN. This finding was
observed in freshly isolated monocytes, and THP-1
monocytes and THP-1 macrophages, since both cell
types are exposed to mycobacterial infection in vivo.
Our data are in agreement with a recent study
demonstrating that type I IFN may induce the
expression of certain chemokine genes,
25 and at the
same time are consistent with a previous report
demonstrating that the ability to respond to the IFN-
ab system is required for normal host defense.
26
Furthermore, our data indicate that neutralization of
endogenous type I IFN, using a neutralizing anti-IFN-
ab antibody, reduced the mRNA steady-state level of
M. bovis-induced CXCL10 expression. It is possible
that secretion of CXCL10 in our system could be
ascribed to the activation of the nuclear factor-
kappaB (NF-kB) pathway. In fact, an early study
has documented that NF-kB may contribute to the
activation of CXCL-8 chemokine genes in M. bovis-
infected human monocytes.
27 Therefore, our obser-
vations do not exclude the possibility that the
secretion of CXCL10 is regulated in M. bovis-infected
human monocytes, at least, in two ways: first, by the
direct interaction between M. bovis and human
monocytes leading to the activation of the NF-kB
complex; and, second, by the effect of type I IFN. We
are currently investigating this possibility.
An early study documented a role for interleukin
(IL)-12 in chemokine gene expression.
28 Therefore,
our results do not allow us to exclude the possibility
of a feedback loop, where CXCL10 secretion pre-
cedes IL-12 and the subsequent increased levels of
CXCL10 gene expression are dependent upon both
IL-12 and IFN. However, it has been demonstrated
that chemokines do not upregulate IL-12, and in fact
downregulate its secretion.
2931
There is conflicting evidence on the role of IFN-ab
during mycobacterial infection. On one hand, it has
been shown that the administration of aerosolized
IFN-a to patients receiving antimicrobial treatment
for pulmonary tuberculosis lead to a more rapid
decrease in the number of bacilli identified in sputum
and earlier resolution of fever and some radiographic
abnormalities.
3234 Moreover, Cooper et al.
35 re-
cently showed a statistically significant increase in
mycobacterial burden during the first 40 days post-
infection in the lungs of mice having a null mutation
in the IFN-a/b receptor, suggesting that type I IFN
can play a defensive role during M. tuberculosis
infection. Conversely, it has been demonstrated that,
in mice, the induction of type I IFN by M. tubercu-
losis infection may be pathogenic, since the intrana-
sal administration of IFN-ab to infected mice
increases the bacterial burden and decreases the
median survival time compared with infection
alone.
36 However, it is well known that rapidly
proliferating mycobacteria are more sensitive to
antimicrobials. Therefore, enhanced mycobacterial
replication induced by IFN-a could lead to the earlier
response seen in patients with tuberculosis treated
with type I IFN. As judged by the effects of IFN-a on
M. bovis-induced CXCL10 expression, the data pre-
sented here suggest another pathway through which
the type I IFN system can play a defensive role in
FIG. 5. IFN-ab mediates induction of CXCL10 gene expres-
sion in M. bovis-infected human monocytes. Total cellular
RNA was isolated from M. bovis-infected human monocytes,
treated with 10 mg/ml of a neutralizing anti-IFN-ab antibody
for 24 h, and the levels of (A) CXCL10 mRNA or (B) CXCL8
mRNA were measured by a semi-quantitative RT-PCR meth-
od. Controls were treated either with medium or with M.
bovis alone. GAPDH served as an internal control. This is a
representative RT-PCR experiment, which was repeated an
additional three times with RNA extracted from different cell
cultures.
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IFN regulates M. bovis-induced CXCL10 chemokine
expression in vivo will require further study.
In conclusion, the present investigation demon-
strates that in vitro CXCL10 is expressed in M. bovis-
infected human monocytes and that type I IFN plays
a crucial role in regulating this expression. Further
investigation of the importance of M. bovis-induced
CXCL10 secretion in the regulation of the immune
response against M. tuberculosis has to be confirmed
in vivo. However, the functional relationship be-
tween chemokines and cytokines will undoubtedly
be crucial to the understanding of protective immune
response against tuberculosis.
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